09/09/2026
For Nancy and Rick, a new pancreatic cancer treatment means the possibility of more time together.
Nancy was diagnosed with pancreatic cancer just after Christmas last year. After searching for the latest treatment options and ultimately becoming a patient at MUSC Hollings Cancer Center, she and her family waited months for access to daraxonrasib, a promising new targeted therapy.
That wait ended in August, when Nancy learned she could finally begin the treatment.
“I plan on living a long, active and fulfilling life,” she said. “This new drug will help me to achieve this goal.”
Daraxonrasib recently received FDA approval after a phase III clinical trial showed it nearly doubled median survival for patients with metastatic pancreatic cancer compared with chemotherapy.
For Dr. Craig Lockhart, Nancy’s oncologist, the results represent a remarkable moment in pancreatic cancer care. For Nancy and Rick, they represent something more personal: more time to spend with family, friends and each other.
Read their story:
https://musc.co/4cqkihc